PO-EVLPs通过递送miR159-y并抑制TGFBR2的表达,缓解炎症性肠病和结肠炎相关结直肠癌,进而调节固有淋巴细胞的表型可塑性。
PO-EVLPs alleviate inflammatory bowel disease and colitis-associated colorectal cancer by delivering miR159-y and suppressing TGFBR2 expression, thereby modulating the phenotypic plasticity of innate lymphoid cells.
Hao Zhong, Zhuoya Liu, Zixuan Zhao, Shujia Yao, Deyang Ning, Hongzhi Qiao, Haiyang Yu
Journal:Acta Pharmaceutica Sinica B
IF:14.6
DOI:10.1016/j.apsb.2026.07.044
PMID:
Published:2026-07-31
research field:分子生物学植物遗传学植物病理学
Abstract
Inflammatory bowel disease (IBD) and its progression to colitis-associated colorectal cancer (CAC) pose significant clinical challenges due to their complex pathogenesis and limited therapeutic options. Plant-derived extracellular vesicle-like particles (PEVLPs) have emerged as promising candidates for targeted therapy, owing to their biocompatibility and intrinsic bioactivity. Here, we isolated and characterized Portulaca oleracea L.-derived extracellular vesicle-like particles (PO-EVLPs) and demonstrated their preferential accumulation in the colon of mouse models through systematic biodistribution studies. Mechanistically, PO-EVLPs exert therapeutic effects via the delivery of miRNAs. Specifically, the enriched miR159-y suppresses TGF- β receptor expression, thereby promoting the expansion of group 3 innate lymphoid cells (ILC3s) in colitic tissues. Furthermore, during the transition from chronic inflammation to carcinogenesis, miR159-y-mediated inhibition of TGF- β receptors prevents TGF- β -driven differentiation of NK cells into ILC1s and the conversion of ILC3s into regulatory innate lymphoid cells (ILCregs), thereby impeding CAC progression. In vivo studies also indicated a favorable safety profile. These findings establish PEVLPs as a multifunctional therapeutic platform that simultaneously targets inflammatory pathways and neoplastic transformation, offering a novel strategy for managing IBD and CAC by precisely modulating mucosal immunity.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


